Clobetasol Propionate

Clobetasol Propionate (0.05% w/w) is an ultra-high potency (Class I) topical synthetic corticosteroid on the WHO Model List of Essential Medicines. It binds to intracellular glucocorticoid receptors, down-regulating inflammatory cytokines (IL-1, IL-2, TNF-alpha) and inducing lipocortins to block phospholipase A2 and arachidonic acid cascade products. Indicated for short-term management of moderate-to-severe plaque psoriasis, recalcitrant dermatoses, lichen planus, and severe discoid lupus erythematosus.

Clobetasol Propionate (0.05%) combined with antibacterial (Gentamicin/Neomycin) and/or antifungal (Miconazole) agents. Delivers rapid anti-inflammatory and anti-pruritic relief while providing broad-spectrum coverage against secondary bacterial and candidal/dermatophyte infections in steroid-responsive dermatoses. Indicated for infected inflammatory dermatoses, infected eczema, and severe intertrigo.

Clobetasol Propionate (0.05%) combined with antibacterial (Gentamicin/Neomycin) and/or antifungal (Miconazole) agents. Delivers rapid anti-inflammatory and anti-pruritic relief while providing broad-spectrum coverage against secondary bacterial and candidal/dermatophyte infections in steroid-responsive dermatoses. Indicated for infected inflammatory dermatoses, infected eczema, and severe intertrigo.

Clobetasol Propionate (0.05%) combined with antibacterial (Gentamicin/Neomycin) and/or antifungal (Miconazole) agents. Delivers rapid anti-inflammatory and anti-pruritic relief while providing broad-spectrum coverage against secondary bacterial and candidal/dermatophyte infections in steroid-responsive dermatoses. Indicated for infected inflammatory dermatoses, infected eczema, and severe intertrigo.

Clobetasol Propionate (0.05%) combined with antibacterial (Gentamicin/Neomycin) and/or antifungal (Miconazole) agents. Delivers rapid anti-inflammatory and anti-pruritic relief while providing broad-spectrum coverage against secondary bacterial and candidal/dermatophyte infections in steroid-responsive dermatoses. Indicated for infected inflammatory dermatoses, infected eczema, and severe intertrigo.

Clobetasol Propionate (0.05%) and Salicylic Acid (3% or 6%) ointment is a potent keratolytic-corticosteroid combination for hyperkeratotic dermatoses. Clobetasol is an ultra-high potency (Class I) topical corticosteroid that produces rapid vasoconstriction, anti-inflammatory, and immunosuppressive actions, while salicylic acid dissolves the intercellular cement of the stratum corneum, desquamating thick adherent scales and enhancing the penetration of clobetasol into the dermis. Indicated for chronic plaque psoriasis, palmoplantar psoriasis, lichen planus, hypertrophic lichen simplex chronicus, and severe hyperkeratotic eczema.

Clobetasol Propionate (0.05%) and Salicylic Acid (3% or 6%) ointment is a potent keratolytic-corticosteroid combination for hyperkeratotic dermatoses. Clobetasol is an ultra-high potency (Class I) topical corticosteroid that produces rapid vasoconstriction, anti-inflammatory, and immunosuppressive actions, while salicylic acid dissolves the intercellular cement of the stratum corneum, desquamating thick adherent scales and enhancing the penetration of clobetasol into the dermis. Indicated for chronic plaque psoriasis, palmoplantar psoriasis, lichen planus, hypertrophic lichen simplex chronicus, and severe hyperkeratotic eczema.

Clobetasol Propionate (0.05%) combined with antibacterial (Gentamicin/Neomycin) and/or antifungal (Miconazole) agents. Delivers rapid anti-inflammatory and anti-pruritic relief while providing broad-spectrum coverage against secondary bacterial and candidal/dermatophyte infections in steroid-responsive dermatoses. Indicated for infected inflammatory dermatoses, infected eczema, and severe intertrigo.

Clobetasol Propionate (0.05% w/w) is an ultra-high potency (Class I) topical synthetic corticosteroid on the WHO Model List of Essential Medicines. It binds to intracellular glucocorticoid receptors, down-regulating inflammatory cytokines (IL-1, IL-2, TNF-alpha) and inducing lipocortins to block phospholipase A2 and arachidonic acid cascade products. Indicated for short-term management of moderate-to-severe plaque psoriasis, recalcitrant dermatoses, lichen planus, and severe discoid lupus erythematosus.

Nadifloxacin (1% w/w cream) is a synthetic broad-spectrum fluoroquinolone bactericidal antibacterial agent for topical dermatological use. It inhibits bacterial DNA gyrase (topoisomerase II), blocking bacterial DNA replication against Cutibacterium acnes, Staphylococcus epidermidis, and methicillin-resistant S. aureus (MRSA). Indicated for acne vulgaris, folliculitis, and superficial bacterial skin infections.